Fachärztin für Dermatologie, Venerologie, Allergologie und Naturheilverfahren

Publikationen

1. Wilhelm K, Wilsmann-Theis D, Sommer T, Leutner C, Textor J, Schild H. CT angiography hemodynamically relevant to renal artery stenosis. Evaluation of AXIAL, MPR, MIP and SSD reconstruction procedures under standard investigation conditions. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2000 Feb;172(2):161-7

2. Wilsmann-Theis D, Wenzel J, Gerdsen R, Uerlich M, Bieber T; Granuloma annulare induced by scabies. Acta Derm Venereol. 2003;83(4):318.

3. Wenzel J, Bokemeyer D, Wilsmann D, Gerdsen R, Tueting T, Uerlich M, Bieber T. Bullous lupus erythematosus in a patient with pre-existing dermatomyositis. Rheumatol Int. 2004 Mar;24(2):114-6.

4. Wilsmann-Theis D, Hagemann T, Dederer H, Wenzel J, Bieber T, Novak N. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol. 2004 Jun;150(6):1194-7.

5.Wenzel J, Montag S, Wilsmann-Theis D, Gaffal E, Bieber T, Tüting T. Successful treatment of recalcitrant Wegener’s granulomatosis of the skin with tacrolimus (Prograf). Br J Dermatol. 2004 Oct;151(4):927-8.

6. Hofmann H, Choi SM, Wilsmann-Theis D, Horré R, de Hoog GS, Bieber T. Invasive chromoblastomycosis and sinusitis due to Phialophora verrucosa in a child from northern Africa. Mycoses. 2005 Nov;48(6):456-61.

7. Wilsmann-Theis D, Martin S, Reber M, Kwiek B, Bieber T, Novak N. Biologicals dramatic advances in the treatment of psoriasis. Curr Pharm Des. 2006;12(8):989-99.

8. Wilsmann-Theis D. Aktuelle Aspekte in der systemischen Therapie der Psoriasis vulgaris. HAUT, 6/2006 Band XVII 222-226

9. Wilsmann-Theis D. Schuppenflechte – was tun? ÄRZTLICHE PRAXIS Pädiatrie 3_2007: 38-41

10. Wilsmann-Theis D, Wenzel J, Betten HH, Kukuk G, Bieber T, Schmid-Wendtner MH. A rapidly growing squamous cell carcinoma or keratoacanthoma or both? Acta Derm Venereol. 2007;87(5):447-8.

11. Wilsmann-Theis D, Hagemann T, Jordan J, Bieber T, Novak N. Facing Psoriasis and Atopic eczema: Are there more Similarities or Differences? Eur J Dermatol 2008; 18(2): 1-9

12. Jordan J., Wilsmann-Theis D. Psoriasis Pustulosa. Eine besondere Herausforderung für innovative Therapeutika. Haut 2008; 19.3: 120.

13. Jordan J, Mey U, Bieber T, Wilsmann-Theis D. Paradoxical Exacerbation of Psoriasis during Therapy with Fludarabine. Eur J Dermatol 2008; 18(3): 25-26

14. Ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum – another cutaneous side effect of sunitinib? Br J Dermatol 2008 May: 15

15. Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology, 2008;217(4):343-6

16. Jordan J, Bieber T, Wilsmann-Theis D. Quick remission of Psoriasis associated with reversible Leucopenia after two Injections with Adalimumab . Clin Exp Dermatol. 2009 Dec;34(8):1004-5.

17. Wilsmann-Theis D, Sareika F, Bieber T, Schmid-Wendtner MH, Wenzel J. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):235-7.

18. Mößner R, Wilsmann-Theis D, Schön MP. Kurzbewertungen: Ustekinumab (Stelara). Arzneimittel-, Therapie-Kritik & Medizin und Umwelt. 2011;43(1):27 1434-5730

19. Hinz T, Wilsmann-Theis D, Buchner A, Wenzel J, Wendtner CM, Bieber T, Reinhard G, Baumert J, Schmid-Wendtner MH. High-resolution ultrasound combined with power Doppler sonography can reduce the number of sentinel lymph node biopsies in cutaneous melanoma. Dermatology. 2011;222(2):180-8

20. Philipp S, Wilsmann-Theis D*, Weyergraf A, Rotterdam S, Frambach Y, Gerdes S, Mössner R. Combination of adalimumab with traditional systemic antipsoriatic drugs – a report of 39 cases. J Dtsch Dermatol Ges. 2012 Aug 31.1.

 21.Mrowietz U, Altmeyer P, Augustin M, Boehncke WH, Bonnekoh B, Frambach Y, Gambichler T, Ghoreschi K, Hertl M, Hund AC, Jacobi A, Kuhn A, Ludwig RJ, Luger T, Martin SF, Merk H, Norgauer J, Reich K, Rostami-Yazdi M, Sabat R, Schäkel K, Scharffetter-Kochanek K, Schön MP, Scola N, Sticherling M, Thaci D, Wilsmann-Theis D, Viehweg A, Wozel G, Zouboulis CC, Neureither M. J Dtsch Dermatol Ges. 2012 Dec;10 Suppl 8:1-15. doi: 10.1111/j.1610-0379.2012.08047.x.

22. Wilsmann-Theis D, Fronhoffs K, Ehler LK, Wenzel J, Bieber T, Klingmueller K. Low dose methotrexate- a therapeutical kick in TNF-alpha antagonist treatment for recalcitrant psoriasis vulgaris –Therapeutic Hotline-Dermatol Ther. 2014 Jan;27(1):55-9. doi: 10.1111/dth.12046. Epub 2013 Apr 2.

23. D. Wilsmann-Theis, S. Koch, C. Mindnich, S. Bonness, S. Schnautz, D. von Bubnoff & T. Bieber. Generation and functional analysis of human TNF-alpha/iNOS-producing dendritic cells (Tip-DC). Allergy 2013 Jul;68(7):890-8.

24. Körber A., Mössner R, Renner R, Sticht H, Wilsmann-Theis D, Schulz P, Sticherling M, Traupe H, HüffmeierU. Mutations in IL36RN in patients with generalized pustular psoriasis. JID. J Invest Dermatol. 2013 Nov;133(11):2634-2637.

25. Micali G, Wilsmann-Theis D, Mallbris L, Gallo G, Marino V, Brault Y, Germain JM. Etanercept reduces Symptoms and Severity of Psoriasis After Cessation of Cyclosporine Therapy: Results of the SCORE Study. Acta Derm Venereol. 2014 Mar 25. doi: 10.2340/00015555-1845

26. Wilsmann-Theis D, Bieber T. Psoriasis and eczema on the scalp. Hautarzt.2014, Dec;65(12):1043-9

 27.D’Erme AM, Wilsmann-Theis D, Wagenpfeil J, Hölzel M, Ferring-Schmitt S, Sternberg S, Wittmann M, Peters B, Bosio A, Bieber T, Wenzel J. IL-36γ (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol.2015 Apr;135(4):1025-32.

28. Wilsmann-Theis D, Frambach Y, Philipp S, Weyergraf AJ, Jacobi A, Mössner R, Gerdes S. Systemic antipsoriatic combination therapy with fumaric acid esters for plaque-type psoriasis: report on 17 cases. Dermatology.2015;230(2):119-27.

29. Ezziddin S, Khalaf F, Seidel M, Al Zreiqat A, Wilsmann-Theis D, Simon B, Biersack HJ, Sabet A. Introduction of a metabolic joint asymmetry score derived from conventional bone scintigraphy. A new tool to differentiate psoriatic from rheumatoid arthritis. Nuklearmedizin.2015;54(4):183-9.

30. Mössner R, Frambach Y, Wilsmann-Theis D, Löhr S, Jacobi A, Weyergraf A, Müller M, Philipp S, Renner R, Traupe H, Burkhardt H, Kingo K,Kõks S, Uebe S, Sticherling M, Sticht H, Oji V, Hüffmeier U Palmoplantar Pustular Psoriasis Is Associated with Missense Variants in CARD14, but not with Loss-of-Function Mutations in IL36RN in European Patients. J Invest Dermatol.2015 Oct;135(10):2538-41.

31. Wilsmann-Theis D, Wagenpfeil J, Holzinger D, Roth J, Koch S, Schnautz S, Bieber T, Wenzel J. Among the S100 proteins, S100A12 is the most significant marker for psoriasis disease activity. J Eur Acad Dermatol Venereol.2015 Sep 2.

32. Warren RB, Mrowietz U, von Kiedrowski R, Niesmann J, Wilsmann-Theis D, Ghoreschi K, Zschocke I, Falk TM, Blödorn-Schlicht N, Reich K. An intensified dosing schedule of subcutaneous            methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Feb                      4;389(10068):528-537.

33. Wilsmann-Theis D, Jacobi A, Frambach Y, Philipp S, Weyergraf A, Schill T, Steinz K, Gerdes S, Mössner R. Palmoplantar pustulosis – a cross-sectional analysis in Germany. Dermatol Online J.       2017 Apr 15;23(4).

34. Weisenseel P, Wilsmann-Theis, Kahl C, Reich K, Mössner R. Pustular psoriasis. Hautarzt. 2016 Jun;67(6):445-53.